Trial Profile
Phase I Dose Finding Clinical Trial of Combination Paclitaxel, Carboplatin and Temozolomide for Subjects With Solid Tumor Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Temozolomide (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- 19 Jan 2016 Trial focus changed from Therapeutic use and Adverse events to only Adverse events:- Overall tumor response rate removed from primary endpoint as per ClinicalTrials.gov. record.
- 19 Sep 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.